PET-CT Has Limited Capability for Assessing Extranodal Extension
PET-CT alone is insufficient for detailed assessment of extranodal extension (ENE) and should not be relied upon as the primary imaging modality for this purpose. While PET-CT excels at detecting nodal disease and distant metastases, it lacks the anatomic detail necessary to reliably identify the specific morphologic features that define ENE 1.
Why PET-CT Falls Short for ENE Assessment
The fundamental limitation is that FDG-PET/CT does not provide detailed anatomic delineation needed for detecting upstaging features required for correct staging and surgical planning 1. The ACR Appropriateness Criteria explicitly state that PET/CT may actually overestimate tumor extension 1, making it unreliable for precise ENE characterization.
Comparative Diagnostic Performance
Recent evidence demonstrates clear performance differences:
- CT shows superior specificity (92.1% vs 74.4%) and accuracy (88.6% vs 75.3%) compared to PET-CT for ENE detection 2
- PET-CT has poor sensitivity for ENE (37.5%) despite high specificity (97%) 3
- MRI demonstrates the highest sensitivity (72%) for ENE detection 4
What PET-CT Can Contribute
While inadequate alone, metabolic parameters from PET-CT (SUVmax, MTV, TLG) are significantly higher in ENE-positive patients 4. A 2025 study showed that combining MTV with lymph node size achieved 94.7% accuracy for predicting ENE 5. However, this requires integration with anatomic imaging—not PET-CT in isolation.
The Optimal Imaging Strategy
Contrast-enhanced CT or MRI should be the primary modality for ENE assessment, with specific morphologic criteria including:
- Indistinct nodal margins
- Coalescent nodal masses
- Invasive encasement of adjacent structures
- Shaggy margin sign
- Vanishing border sign 5, 6
PET-CT serves best as an adjunct for detecting distant metastases and synchronous tumors, particularly in stage III-IV disease 1, but should not be used as the sole determinant of ENE status.
Critical Pitfall to Avoid
Do not rely on PET-CT metabolic activity alone to diagnose or exclude ENE. The high false-negative rate (sensitivity 37.5%) means ENE can be missed 3, while overestimation of tumor extension can lead to inappropriate upstaging 1. Always obtain dedicated contrast-enhanced CT or MRI with thin sections for definitive ENE evaluation.